文献速递浆细胞疾病

来那度胺和泊马度胺强效干扰多发性骨髓瘤中髓源性抑制细胞的诱导

Lenalidomide and pomalidomide potently interfere with induction of myeloid-derived suppressor cells in multiple myeloma.
PubMed 文献 · Br J Haematol · 2020-06-19

研究探讨多发性骨髓瘤中髓源性抑制细胞(MDSC)的诱导机制,发现骨髓瘤细胞分泌CCL5和MIF是诱导MDSC的前提,而来那度胺和泊马度胺通过CRBN依赖和非依赖的双向分子效应抑制MDSC诱导。

要点

  • 9株人骨髓瘤细胞系中4株能强效诱导正常外周血单个核细胞转化为单核型MDSC。
  • 骨髓瘤细胞分泌CCL5和MIF是诱导MDSC的必要条件。
  • 来那度胺和泊马度胺通过下调骨髓瘤细胞CCL5/MIF及外周血单个核细胞CCR5/上调IRF8抑制MDSC诱导。

核心结论

  • 来那度胺和泊马度胺通过骨髓瘤细胞和正常外周血单个核细胞中重叠的调控效应抑制MDSC诱导,此为一种新发现的作用。

研究设计与样本

  • 采用transwell共培养体系,将9株人骨髓瘤细胞系与正常外周血单个核细胞共培养,检测MDSC诱导情况。

主要发现

  • 9株受检人骨髓瘤细胞系中4株能强效诱导正常外周血单个核细胞产生单核型MDSC。
  • 骨髓瘤细胞分泌CCL5和MIF是诱导MDSC的前提条件。
  • 来那度胺和泊马度胺通过CRBN依赖和非依赖途径下调骨髓瘤细胞CCL5和MIF,并下调外周血单个核细胞CCR5、诱导IRF8,从而抑制MDSC诱导。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

An increase in immunosuppressive myeloid-derived suppressor cells (MDSCs) is associated with disease progression and treatment resistance in multiple myeloma (MM). We investigated the mechanisms underlying MDSC induction, and sought to discover a strategy for prevention of MDSC induction in MM. Using a transwell co-culture system, four of nine examined human myeloma-derived cell lines (HMCLs) were potent in inducing monocytic (M)-MDSCs from normal peripheral blood mononuclear cells (PBMCs). As the results, we identified that secretion of C-C motif chemokine ligand 5 (CCL5) and macrophage migration inhibitory factor (MIF) by myeloma cells is a prerequisite for induction of MDSCs in MM. The immunomodulatory drug (IMiD) compounds, such as lenalidomide (LEN) and pomalidomide (POM), were identified as potent inhibitors of MDSC induction through bidirectional molecular effects of cereblon (CRBN)-dependent and -independent downregulation of CCL5 and MIF in myeloma cells; and downregulation of C-C motif chemokine receptor 5, a receptor for CCL5, and induction of interferon regulatory factor 8, a critical transcription factor for monocytic differentiation, in PBMCs. In the present study of the molecular mechanisms underlying MDSC induction, we identified a novel effect of LEN and POM of inhibiting MDSC induction via overlapping regulatory effects in myeloma cells and normal PBMCs.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Kuwahara-Ota S, Shimura Y, Steinebach C, et al. Lenalidomide and pomalidomide potently interfere with induction of myeloid-derived suppressor cells in multiple myeloma. Br J Haematol. 2020. PMID: 32558939. doi:10.1111/bjh.16881

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。